Crohn's disease and ulcerative colitis, the 2 major forms of inflammatory bowel disease (IBD) in humans, arise in genetically predisposed individuals because of an abnormal immune response direct against constituents of the gut flora. Defects in counter-regulatory mechanisms are supposed to amplify and maintain the IBD-associated mucosal inflammation. Therefore, restoring the balance between inflammatory and anti-inflammatory pathways in the gut could contribute to halt the IBD-associated tissue-damaging immune response. Various suppressive T cell (Tregs) subsets have been characterized phenotypically and functionally and over the last decade, there has been enormous effort for optimizing the procedures for the in vitro expansion/generation of these cells for therapeutic purposes. Here we review the mechanisms of action and functional relevance of Tregs in the maintenance of gut inflammation and analyze the available data about the use of these cells in the treatment of IBD patients.

Fantini, M.c., & Monteleone, G. (2017). Update on the Therapeutic Efficacy of Tregs in IBD: Thumbs up or Thumbs down?. INFLAMMATORY BOWEL DISEASES, 23(10), 1682-1688 [10.1097/MIB.0000000000001272].

Update on the Therapeutic Efficacy of Tregs in IBD: Thumbs up or Thumbs down?

Fantini, Massimo C.;Monteleone, Giovanni
2017

Abstract

Crohn's disease and ulcerative colitis, the 2 major forms of inflammatory bowel disease (IBD) in humans, arise in genetically predisposed individuals because of an abnormal immune response direct against constituents of the gut flora. Defects in counter-regulatory mechanisms are supposed to amplify and maintain the IBD-associated mucosal inflammation. Therefore, restoring the balance between inflammatory and anti-inflammatory pathways in the gut could contribute to halt the IBD-associated tissue-damaging immune response. Various suppressive T cell (Tregs) subsets have been characterized phenotypically and functionally and over the last decade, there has been enormous effort for optimizing the procedures for the in vitro expansion/generation of these cells for therapeutic purposes. Here we review the mechanisms of action and functional relevance of Tregs in the maintenance of gut inflammation and analyze the available data about the use of these cells in the treatment of IBD patients.
Pubblicato
Rilevanza internazionale
Recensione
Esperti anonimi
Settore MED/12 - Gastroenterologia
English
Con Impact Factor ISI
colitis; inflammatory bowel disease; regulatory T cells; TGF-beta; Immunology and Allergy; Gastroenterology
http://journals.lww.com/ibdjournal/pages/default.aspx
Fantini, M.c., & Monteleone, G. (2017). Update on the Therapeutic Efficacy of Tregs in IBD: Thumbs up or Thumbs down?. INFLAMMATORY BOWEL DISEASES, 23(10), 1682-1688 [10.1097/MIB.0000000000001272].
Fantini, Mc; Monteleone, G
Articolo su rivista
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2108/192160
Citazioni
  • ???jsp.display-item.citation.pmc??? 11
  • Scopus 15
  • ???jsp.display-item.citation.isi??? 15
social impact